^
Association details:
Biomarker:BRCA2 mutation
Cancer:Triple Negative Breast Cancer
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

77P - BRCA mutations may induce immune-resistance in breast cancer patients treated with IO-only approach: a retrospective analysis. (ID 296)

Published date:
05/07/2023
Excerpt:
We retrospectively evaluated the effect of germline BRCA mutations in consecutive BC patients underwent any-line IO-only treatment...BRCAm pts demonstrated a significantly shorted PFS...In our small retrospective cohort, the presence of a pathogenic mutation in BRCA1/2 genes resulted in reduced benefit to IO-alone approach.